


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


### Listing of Claims

1. (Canceled)
2. (Currently amended) A compound of the Formula (II):



wherein:

Z is -C(=N-O-R<sub>1-2</sub>)- or



X is:

-CH(R<sub>9</sub>)-, or

-CH(R<sub>9</sub>)-alkylene-;

R<sub>1-1</sub> is selected from the group consisting of:

hydrogen,

alkyl, and

aryl,

alkylene-aryl,

~~heteroaryl,~~

alkylene heteroaryl, and

~~alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene heteroaryl substituted by one or~~

~~more substituents selected from the group consisting of:~~

~~halogen,~~  
~~cyano,~~  
~~nitro,~~  
~~alkoxy,~~  
~~dialkylamino,~~  
~~alkylthio,~~  
~~haloalkyl,~~  
~~haloalkoxy, and~~  
~~alkyl,~~  
~~-NH-SO<sub>2</sub>-R<sub>1-4</sub>,~~  
~~-NH-C(O)-R<sub>1-4</sub>,~~  
~~-NH-C(O)-NH<sub>2</sub>,~~  
~~-NH-C(O)-NH-R<sub>1-4</sub>, and~~  
~~-N<sub>3</sub>;~~

R<sub>1-2</sub> and R<sub>1-3</sub> are independently selected from the group consisting of:

hydrogen,  
alkyl,  
heterocyclyl,  
aryl,  
heteroaryl, and

alkyl, heterocyclyl, aryl, or heteroaryl, substituted by one or more substituents

selected from the group consisting of:

halogen,  
cyano,  
alkyl,  
hydroxy,  
hydroxyalkyl,  
alkoxy,  
dialkylamino,

heterocyclyl,

aryl, and

heteroaryl;

~~R<sub>1-4</sub> is selected from the group consisting of:~~

~~alkyl,~~

~~aryl,~~

~~alkylene-aryl,~~

~~heteroaryl,~~

~~alkylene-heteroaryl, and~~

~~alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:~~

~~halogen,~~

~~cyano,~~

~~nitro,~~

~~alkoxy,~~

~~dialkylamino,~~

~~alkylthio,~~

~~haloalkyl,~~

~~haloalkoxy,~~

~~alkyl, and~~

~~-N<sub>3</sub>;~~

Y is selected from the group consisting of:


a bond,


-C(O)-,

-C(S)-,

-S(O)<sub>2</sub>-,

-S(O)<sub>2</sub>-N(R<sub>8</sub>)-,





~~R<sub>A</sub> and R<sub>B</sub> when taken together, form a fused aryl ring, wherein the aryl ring is unsubstituted or substituted by one or more R groups, or substituted by one R<sub>3</sub> group, or substituted by one R<sub>3</sub> group and one R group;~~

R is selected from the group consisting of:


halogen,  
 hydroxy,  
 alkyl,  
 alkenyl,  
 haloalkyl,  
 alkoxy,  
 alkylthio, and  
~~-N(R<sub>9</sub>)<sub>2</sub>;~~

R<sub>2</sub> is selected from the group consisting of:

hydrogen;  
alkyl;  
alkoxyalkyl; and  
hydroxyalkyl alkyl, and alkylene-O-alkyl;


R<sub>3</sub> is selected from the group consisting of:



~~Z' is a bond or O :~~

R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

~~R<sub>5</sub> is selected from the group consisting of:~~



R<sub>6</sub> is selected from the group consisting of =O and =S;

~~R<sub>7</sub> is C<sub>2-7</sub> alkylene;~~

R<sub>8</sub> is selected from the group consisting of hydrogen, C<sub>1-10</sub> alkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkoxy-C<sub>1-10</sub> alkylenyl, hydroxy-C<sub>1-10</sub> alkylenyl, heteroaryl-C<sub>1-10</sub> alkylenyl, and aryl-C<sub>1-10</sub> alkylenyl;

$R_9$  is selected from the group consisting of hydrogen and alkyl;

~~$R_{10}$  is  $C_{3-8}$ -alkylene;~~

A is selected from the group consisting of -O-, -C(O)-, -S(O)<sub>0-2</sub>-, -CH<sub>2</sub>-, and -N(R<sub>4</sub>)-;

~~Q is selected from the group consisting of a bond, C(R<sub>6</sub>), C(R<sub>6</sub>)-C(R<sub>6</sub>), S(O)<sub>2</sub>, C(R<sub>6</sub>)-N(R<sub>8</sub>), W, S(O)<sub>2</sub>-N(R<sub>8</sub>), C(R<sub>6</sub>)-O, C(R<sub>6</sub>)-S, and C(R<sub>6</sub>)-N(OR<sub>9</sub>);~~

V is selected from the group consisting of -C(R<sub>6</sub>)-, -O-C(R<sub>6</sub>)-, -N(R<sub>8</sub>)-C(R<sub>6</sub>)-, and -S(O)<sub>2</sub>-;

~~W is selected from the group consisting of a bond, C(O), and S(O)<sub>2</sub>;~~

and a and b are each independently integers from 1 to 6 with the proviso that  $a + b \leq 7$ ;

$n'$  is an integer from 0 to 4; and

m is 0 or 1; with the proviso that when m is 1, then  $n'$  is 0 or 1;

or a pharmaceutically acceptable salt thereof.

3.-13. (Canceled)

14. (Currently amended) The compound or salt of claim [[4]] 2 wherein m is 0.


15. (Currently amended) The compound or salt of claim [[4]] 2 wherein  $n'$  is 0.

16. (Original) The compound or salt of claim 14 wherein m and  $n'$  are both 0.

17. (Currently amended) The compound or salt of claim [[4]] 2, wherein  $R_3$  is selected from the group consisting of pyridin-3-yl, pyridin-4-yl, 5-(hydroxymethyl)pyridin-3-yl, and 2-ethoxyphenyl.

18. (Canceled)

19. (Previously presented) The compound or salt of claim 2 wherein  $R_2$  is selected from the group consisting of  $C_{1-4}$  alkyl, and  $C_{1-4}$  alkylenyl-O- $C_{1-4}$  alkyl.

20. (Currently amended) The compound or salt of claim 2 wherein X is selected from the group consisting of  $-(\text{CH}_2)_{1-6}-$ ,  $-\text{CH}_2\text{C}(\text{CH}_3)_2-$ , and  $-\text{CH}_2\text{C}(\text{CH}_3)_2\text{CH}_2-$ ,  ~~$-(\text{CH}_2)_2\text{OCH}_2-$ , and  $(\text{CH}_2)_3\text{OCH}_2-$ .~~
21. (Previously presented) The compound or salt of claim 2 wherein  $\text{R}_{1-1}$  is selected from the group consisting of hydrogen,  $\text{C}_{1-4}$  alkyl, and phenyl.
22. (Previously presented) The compound or salt of claim 2 wherein  $\text{R}_{1-2}$  is selected from the group consisting of hydrogen,  $\text{C}_{1-4}$  alkyl, benzyl, and pyridin-2-ylmethyl.
23. (Previously presented) The compound or salt of claim 2 wherein Z is  $-\text{C}(=\text{N}-\text{O}-\text{R}_{1-2})-$ .
24. (Currently amended) The compound or salt of claim 2 wherein Z is 
25. (Previously presented) The compound or salt of claim 2 wherein  $\text{R}_{1-3}$  is selected from the group consisting of hydrogen and  $\text{C}_{1-6}$  alkyl.
26. (Previously presented) The compound or salt of claim 2 or 25 wherein Y is selected from the group consisting of:  
 $-\text{C}(\text{O})-$ ,  
 $-\text{C}(\text{O})-\text{O}-$ ,  
 $-\text{S}(\text{O})_2-$ ,  
 $-\text{C}(\text{O})-\text{N}(\text{R}_8)-$ , and  
 $-\text{C}(\text{S})-\text{N}(\text{R}_8)-$ .
27. (Original) The compound or salt of claim 26 wherein  $\text{R}_8$  is H or  $\text{CH}_3$ .
28. (Previously presented) A pharmaceutical composition comprising a therapeutically

effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.


29. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

30. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

31. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

32.-78. (Canceled)


79. (Currently amended) A compound of the Formula (IV):



IV

wherein:

Z is  $-\text{C}(=\text{N}-\text{O}-\text{R}_{1-2})-$  or



X is  $-\text{CH}(\text{R}_9)-$  or  $-\text{CH}(\text{R}_9)-\text{alkylene}-$ ;

$\text{R}_{1-1}$  is selected from the group consisting of:

hydrogen,

alkyl, and

aryl;

R<sub>1-2</sub> and R<sub>1-3</sub> are independently selected from the group consisting of:

hydrogen,

alkyl,

aryl ~~alkenyl-O~~alkyl, and

alkyl substituted by one or more substituents selected from the group consisting of aryl and heteroaryl;

Y is selected from the group consisting of:

a bond,

-C(O)-,

-S(O)<sub>2</sub>-,

-S(O)<sub>2</sub>-N(R<sub>8</sub>)-,

-C(O)-O-, and

-C(O)-N(R<sub>8</sub>)-;

R is selected from the group consisting of:

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

-N(R<sub>9</sub>)<sub>2</sub>;

R<sub>2</sub> is selected from the group consisting of:

hydrogen,

alkyl,

alkoxyalkyl, and

hydroxyalkyl ~~alkyl, and alkylenyl-O~~alkyl;

$R_3$  is  $-Z'-R_4$  selected from the group consisting of:

halogen,

aryl,

heteroaryl, and

aryl and heteroaryl substituted by one or more of the groups selected from hydroxyl,  $-C(O)NH_2$ ,  $-NHS(O)_2$ -alkyl,  $-C(O)NH$ -alkyl,  $-C(O)NH$ -heterocyclyl;

$Z'$  is a bond;

$R_9$  is selected from the group consisting of hydrogen and alkyl;

$n'$  is 0 or 1;

$m$  is 0 or 1;

~~$R_4$  is selected from the group consisting of: hydrogen, aryl and heteroaryl, wherein the aryl and heteroaryl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; and~~

$R_8$  is selected from the group consisting of hydrogen, or  $C_{1-10}$  alkyl; or a pharmaceutically acceptable salt thereof.

80. (Currently amended) A compound selected from the group groups consisting of:

*N*-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxyacetamide;

1-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-1-methoxyurea;

*N*-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxy-methanesulfonamide;

1-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-butyl]-methoxy-3-phenylurea;

*N*-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-methylbutyl)-*N*-methoxy-acetamide;

1-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-1-methoxy-3-phenylurea;

1-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-3-ethyl-1-methoxyurea;

*N*-[4-(4-amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-*N*-methoxymethanesulfonamide;

5-(4-amino-7-phenyl-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloxime;

1-[4-(4-amino-7-phenyl-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-3-isopropyl-1-methoxyurea;

4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-phenylbutan-1-one-oxime;

4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-phenylbutan-1-one-*O*-methyloxime;

5-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-oxime;

5-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-benzyloxime;

5-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloxime;

5-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloxime;

5-(4-amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-oxime;

5-(4-amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloxime hydrochloride;

5-(4-amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-benzyloxime hydrochloride;

1-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-6-methylheptan-4-one-oxime;

1-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)decan-4-one-oxime;

5-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,4-dimethylpentan-2-one-*O*-methyl-oxime;

5-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,4-dimethylpentan-2-one-*O*-methyloxime;

5-(4-amino-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,4-dimethylpentan-2-one-*O*-methyloxime;

(1*E,Z*)-4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butanal-*O*-methyloxime;

*N*-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-hydroxyacetamide;

*N*-[4-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-hydroxy-*N'*-isopropylurea;

4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butanal-*O*-methyloxime;

*N*-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxyurea;

*N*-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxymethanesulfonamide;

1-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butan-2-one-*O*-methyloxime;

~~*N* { 4 [ 4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*][1,5]naphthyridin-1-yl] 1-methylbutyl }-*N'*-isopropyl-*N*-methoxyurea;~~

*N*-[4-(4-amino-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-hydroxy-*N'*-isopropylurea;

*N*-[3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-*O*-methylhydroxylamine;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-*N*-methoxyhexanamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxycyclohexanecarboxamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-2-methylbenzamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-2-chloro-*N*-methoxybenzamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-3-chloro-*N*-methoxybenzamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-4-chloro-*N*-methoxybenzamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxynicotinamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-1-(methylsulfonyl)methanamide;

*N*-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-1-(m-tolylsulfonyl)methanamide;

N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxy-1-(o-tolylsulfonyl)methanamide;

N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxy-1-tosylmethanamide;

N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-(2-chlorophenylsulfonyl)-N-methoxymethanamide;

N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-(3-chlorophenylsulfonyl)-N-methoxymethanamide;

N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-(4-chlorophenylsulfonyl)-N-methoxymethanamide;

N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)-1-((1S,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-N-methoxymethanesulfonamide;

1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3,3-dimethylthiourea;

1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-3-cyclohexyl-1-methoxyurea;

1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-m-tolylurea;

1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-o-tolylurea;

1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-(pyridin-3-yl)thiourea;

N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxymorpholine-4-carboxamide;

1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-methyl-3-phenylurea;

N-(3-(4-amino-7-bromo-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;

N-(3-(4-amino-7-phenyl-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;

N-(3-(4-amino-2-propyl-7-(pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;

N-(3-(4-amino-2-propyl-7-(pyridin-4-yl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;

N-(3-(4-amino-7-(2-hydroxyphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;

N-(3-(4-amino-7-(3-hydroxyphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;

3-(4-amino-1-(3-(N-methoxyacetamido)butyl)-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl)benzamide; or a pharmaceutically acceptable salt thereof.